Section Arrow
IMVT.NASDAQ
- Immunovant
Quotes are at least 15-min delayed:2026/01/08 07:44 EST
Pre Market
Last
 26.36
-0.37 (-1.38%)
Bid
26.3
Ask
26.9
High 26.81 
Low 26.32 
Volume 194 
Regular Hours (Closed)
Last
 26.73
+0.83 (+3.20%)
Day High 
27.375 
Prev. Close
25.9 
1-M High
27.69 
Volume 
1.75M 
Bid
26.3
Ask
26.9
Day Low
25.9 
Open
26.05 
1-M Low
22.33 
Market Cap 
5.22B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 26.05 
20-SMA 25.68 
50-SMA 24.14 
52-W High 27.69 
52-W Low 12.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.82/-2.50
Enterprise Value
5.22B
Balance Sheet
Book Value Per Share
2.58
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
Pre Market 0.128 +0.0024 +1.91%
ERASErasca5.17+1.54+42.42%-- 
Pre Market 4.55 -0.62 -11.99%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
Pre Market 4.81 -0.05 -1.03%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
Pre Market 13.78 +0.05 +0.36%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
Pre Market 23.35 +0.07 +0.30%
Industry overview quotes are at least 15 minutes delayed
Business Description
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.